doiSerbia

Favourable prognostic factors in therapy related acute myeloid leukaemia

Antonijević Nebojša (Klinika za hematologiju, Klinički centar Srbije, Beograd + Medicinski fakultet, Beograd)
Suvajdžić Nada (Klinika za hematologiju, Klinički centar Srbije, Beograd + Medicinski fakultet, Beograd)
Terzić Tatjana (Institut za patologiju, Medicinski fakultet, Beograd)
Jakovljević Branko (Institut za higijenu i medicinsku ekologiju, Medicinski fakultet, Beograd)
Janković Gradimir (Klinika za hematologiju, Klinički centar Srbije, Beograd + Medicinski fakultet, Beograd)
Elezović Ivo (Klinika za hematologiju, Klinički centar Srbije, Beograd)
Milošević Rajko (Klinika za hematologiju, Klinički centar Srbije, Beograd)
Čolović Milica (Klinika za hematologiju, Klinički centar Srbije, Beograd + Medicinski fakultet, Beograd)

Introduction. Therapy related acute myeloid leukaemia (t-AML) is a distinct clinical entity recognized by the World Health Organization classification occurring after chemotherapy and/or radiation treatment administered for a previous disease. T-AML is characterised by pancytopenia, three-lineage myelodysplasia, high frequency of unfavourable cytogenetics and short survival. Objective. The aim of this study was to analyse clinical, cytogenetic, and cytological characteristics of t-AML and their impact on survival. Methods. Seventeen patients with t-AML (8 male and 9 female; median age 59 years) were identified among 730 consecutive patients with acute myeloid leukaemia. The degree of three-lineage dysplasia as well as haematological, cytological and cytogenetic analyses, were assessed by standard methods. Results. The patients survived a median of 62.5 days with the 10% probability of survival during two years. Prognostically favourable factors were a higher percentage of dysplastic granulocytic cells, age less than 60 years, and presence of prognostically favourable karyotype inv(16), t(15;17), t(8;21). Conclusion. The stated prognostic factors that include age, cytogenetics findings and granulocytic dysplasia analysis could contribute to adequate risk stratification of t-AML, though fuller results would require additional analyses.

Keywords: therapy related acute myeloid leukaemia, cytology, myelodysplasia, survival